Get Allogene Therapeutics alerts: "Next generation cell therapy is shifting from promise to proof," Chang said, adding that the company's strategy is focused on "differentiated clinical evidence rather than platform ambition alone." Cema-cel interim analysis shows MRD clearance signal Allogene Therapeutics NASDAQ: ALLO said its first quarter of 2026 was marked by early clinical progress for its lead allogeneic CAR-T programs and a strengthened cash position following an April financing. On the company's qua ...